1997 Annual Report
Product Review Financials Setting  
  |Product Pipeline      
|Product Portfolio

| Cardiovascular Diseases | Central Nervous System Disorders | Infectious Diseases |
| Arthritis/Inflammation | Metabolic Diseases | Allergic Diseases |
| Cancer | Genitourinary/Sexual Health | Surgery/Interventional |
| Consumer Health/OTC | Animal Health |
 

   
MAJOR PFIZER PRODUCTS AND SELECTED CANDIDATES IN DEVELOPMENT
Allergic Diseases
Current Products
Reactine [I]3
Zyrtec [U.S.]3
(tablets and syrup)
Extensions / Additional Indications (last 12 months) Under Regulatory Review In Advanced-Stage Development
  Zyrtec [U.S.]
(for pediatric use,
ages 2-5)
Zyrtec-D
(cetirizine HCl and pseudoephedrine HCl)
Key: [U.S.]—U.S. only    [I]—International only (in at least one country)
No Key—Both U.S. and at least one other country

3Copromoted by UCB Pharmaceuticals and Pfizer; trademark of UCB

  letter back top next
  Logo Imagemap
  intended for investors
  Advisory Information for Investors
  Copyright © 1997, 1998 Pfizer Inc All rights reserved.